General Proximity: Ambitious Platform, Zero Publications
General Proximity claims its OmniTAC platform extends induced proximity beyond degradation to activation, refolding, and re-localization, but has zero publications — a Daiichi Sankyo oncology collaboration is the strongest external signal to date.
A small molecule brings two proteins together; one of them changes. The principle — induced proximity — is established in drug discovery.
General Proximity (San Francisco, 2019) claims its OmniTAC platform is not limited to one mechanism. Degradation, activation, refolding, re-localization, re-programming, functional modulation — the platform discovers target–effector pairs for different biological tasks.
If the platform works as claimed, it reaches targets "previously beyond the reach of medicine" (GP's language). Disease areas: neurodegeneration, cardiometabolic disease, oncology.
We cannot verify any of this yet. Zero publications, no published preclinical result. The company raised $16M in a seed round (January 2025) and received an NIH NCI SBIR Phase I grant — but the science remains closed.
In November 2025, GP announced a multi-target oncology collaboration with Daiichi Sankyo. Not proof that OmniTAC works, but the strongest external signal so far.
The aging connection is our framing: GP's stated disease areas — neurodegeneration, cardiometabolic disease, oncology — overlap with age-related pathology. Eternal Search rating: 9.98 out of 100 — publications 0/10, results 2/10. Not enough data for a meaningful verdict yet.
Next post — the team behind General Proximity.
Company page →
Induced proximity is proven biology with approved drugs (PROTACs, molecular glues), making GP's extension claim plausible in principle. But the company has disclosed zero results, targets, or molecules, creating a clear case study in distinguishing platform logic from platform evidence. The Daiichi Sankyo collaboration is the one verifiable external signal. This teaches readers how to read early-stage biotech honestly.